{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:16:20Z","timestamp":1778944580620,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20171BAB205044"],"award-info":[{"award-number":["20171BAB205044"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["GZ2019ZSF172"],"award-info":[{"award-number":["GZ2019ZSF172"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.leukres.2025.107646","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:33:34Z","timestamp":1736379214000},"page":"107646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Blood cancer therapy with synthetic receptors and CRISPR technology"],"prefix":"10.1016","volume":"150","author":[{"given":"Haiying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-0363","authenticated-orcid":false,"given":"Changkun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2025.107646_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41551-022-00895-1","article-title":"Synthetic libraries of immune cells displaying a diverse repertoire of chimaeric antigen receptors as a potent cancer immunotherapy","volume":"6","author":"Fu","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ccell.2022.03.009","article-title":"Synthetic HLA-independent T cell receptors for cancer immunotherapy","volume":"40","author":"Simon","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.leukres.2025.107646_bib3","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1021\/acssensors.4c01997","article-title":"SynNotch-Programmed Macrophages for Cancerous Cell Detection and Sensing","volume":"9","author":"Wang","year":"2024","journal-title":"ACS Sens"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2025.107646_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11596-021-2391-5","article-title":"Combination of CRISPR\/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies","volume":"41","author":"Hu","year":"2021","journal-title":"Curr. Med Sci."},{"key":"10.1016\/j.leukres.2025.107646_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2020.07.015","article-title":"CRISPR\/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy","volume":"158","author":"Huang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.leukres.2025.107646_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/crispr.2018.0026","article-title":"Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research","volume":"1","author":"Lau","year":"2018","journal-title":"CRISPR J."},{"issue":"5","key":"10.1016\/j.leukres.2025.107646_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11248-024-00404-x","article-title":"Next-generation CRISPR technology for genome, epigenome and mitochondrial editing","volume":"33","author":"Lau","year":"2024","journal-title":"Transgenic Res"},{"key":"10.1016\/j.leukres.2025.107646_bib9","first-page":"1","article-title":"Amplification-free nucleic acids detection with next-generation CRISPR\/dx systems","author":"Lau","year":"2024","journal-title":"Crit. Rev. Biotechnol."},{"issue":"11","key":"10.1016\/j.leukres.2025.107646_bib10","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.leukres.2025.107646_bib11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib12","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41467-017-02075-1","article-title":"Engineering cell sensing and responses using a GPCR-coupled CRISPR-Cas system","volume":"8","author":"Kipniss","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.leukres.2025.107646_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091929","article-title":"Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR\/Cas9-Based Genome Editing","volume":"9","author":"Sgodda","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.leukres.2025.107646_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41589-021-00926-z","article-title":"The evolution of synthetic receptor systems","volume":"18","author":"Manhas","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-023-01680-5","article-title":"Programmable synthetic receptors: the next-generation of cell and gene therapies","volume":"9","author":"Teng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"6382","key":"10.1016\/j.leukres.2025.107646_bib16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6230","key":"10.1016\/j.leukres.2025.107646_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.leukres.2025.107646_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2024.06.023","article-title":"Preclinical efficacy of a HER2 synNotch\/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification","author":"Cortese","year":"2024","journal-title":"Mol. Ther."},{"issue":"591","key":"10.1016\/j.leukres.2025.107646_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"591","key":"10.1016\/j.leukres.2025.107646_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib23","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nat. Commun."},{"issue":"6520","key":"10.1016\/j.leukres.2025.107646_bib24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1126\/science.abc6270","article-title":"Precise T cell recognition programs designed by transcriptionally linking multiple receptors","volume":"370","author":"Williams","year":"2020","journal-title":"Science"},{"issue":"6534","key":"10.1016\/j.leukres.2025.107646_bib25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.leukres.2025.107646_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"7925","key":"10.1016\/j.leukres.2025.107646_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature"},{"issue":"7643","key":"10.1016\/j.leukres.2025.107646_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107646_bib29","doi-asserted-by":"crossref","unstructured":"M. Wang, J.B. Krueger, A.K. Gilkey, E.M. Stelljes, M.G. Kluesner, E.J. Pomeroy, J.G. Skeate, N.J. Slipek, W.S. Lahr, P.N.C. Vazquez, Y. Zhao, E.J. Eaton, K. Laoharawee, B.R. Webber, B.S. Moriarity, Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing, bioRxiv (2024).","DOI":"10.1101\/2024.03.05.582637"},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.2022018658","article-title":"Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy","volume":"143","author":"Tang","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2025.107646_bib31","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.celrep.2017.08.044","article-title":"Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors","volume":"20","author":"Baeumler","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12967-021-03132-6","article-title":"Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers","volume":"19","author":"Yang","year":"2021","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.leukres.2025.107646_bib33","doi-asserted-by":"crossref","DOI":"10.1089\/crispr.2024.0036","article-title":"Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects","author":"George","year":"2024","journal-title":"CRISPR J."},{"key":"10.1016\/j.leukres.2025.107646_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.pmbts.2024.07.004","article-title":"Advances in CRISPR-Cas systems for blood cancer","volume":"208","author":"Monchusi","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"5","key":"10.1016\/j.leukres.2025.107646_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1080\/21645515.2019.1571893","article-title":"CRISPR\/Cas9-based genome editing in the era of CAR T cell immunotherapy","volume":"15","author":"Salas-Mckee","year":"2019","journal-title":"Hum. Vaccin Immunother."},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib36","article-title":"CRISPR, CAR-T, and NK: Current applications and future perspectives","volume":"11","author":"Khoshandam","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.leukres.2025.107646_bib37","doi-asserted-by":"crossref","first-page":"1354825","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcyt.2021.10.010","article-title":"Use of CRISPR\/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies","volume":"24","author":"Maganti","year":"2022","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib39","first-page":"419","article-title":"Detection of cancer by tumor markers in the blood: a view to the future","volume":"4","author":"Sell","year":"1993","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.leukres.2025.107646_bib40","first-page":"45","article-title":"[New classification of leukemia]","volume":"115","author":"Tomonaga","year":"2001","journal-title":"Rinsho Byori Suppl."},{"issue":"5","key":"10.1016\/j.leukres.2025.107646_bib41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.107646_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.semnuclmed.2005.02.002","article-title":"Staging and classification of lymphoma","volume":"35","author":"Lu","year":"2005","journal-title":"Semin Nucl. Med"},{"issue":"5","key":"10.1016\/j.leukres.2025.107646_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00001622-199509000-00003","article-title":"Revised European-American Lymphoma Classification","volume":"7","author":"Pileri","year":"1995","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.leukres.2025.107646_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106687","article-title":"Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment","volume":"111","author":"Gowin","year":"2021","journal-title":"Leuk. Res"},{"issue":"7","key":"10.1016\/j.leukres.2025.107646_bib45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2025.107646_bib46","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"6121","key":"10.1016\/j.leukres.2025.107646_bib47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.leukres.2025.107646_bib48","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"C.A.R.T.G. Base-Edited, Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.leukres.2025.107646_bib49","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2025.107646_bib50","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nmeth.4327","article-title":"CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations","volume":"14","author":"Kuscu","year":"2017","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.leukres.2025.107646_bib51","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.molcel.2017.08.008","article-title":"CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons","volume":"67","author":"Billon","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41467-017-00687-1","article-title":"In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting","volume":"8","author":"Chen","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.leukres.2025.107646_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky222","article-title":"Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption","volume":"46","author":"Gopalappa","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.leukres.2025.107646_bib54","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","article-title":"Inserting EF1alpha-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.leukres.2025.107646_bib55","article-title":"CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells","volume":"10","author":"Liao","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.leukres.2025.107646_bib56","doi-asserted-by":"crossref","unstructured":"J. Kath, C. Franke, V. Drosdek, W. Du, V. Glaser, C. Fuster-Garcia, M. Stein, T. Zittel, S. Schulenberg, C.E. Porter, L. Andersch, A. Kunkele, J. Alcaniz, J. Hoffmann, H. Abken, M. Abou-El-Enein, A. Pruss, M. Suzuki, T. Cathomen, R. Stripecke, H.D. Volk, P. Reinke, M. Schmueck-Henneresse, D.L. Wagner, Integration of zeta-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells, bioRxiv (2023).","DOI":"10.1182\/blood.2023020973"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00438-024-02167-w","article-title":"Development of a baculoviral CRISPR\/Cas9 vector system for beta-2-microglobulin knockout in human pluripotent stem cells","volume":"299","author":"Xiang","year":"2024","journal-title":"Mol. Genet Genom."},{"key":"10.1016\/j.leukres.2025.107646_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/nature17664","article-title":"Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9","author":"Paquet","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib59","doi-asserted-by":"crossref","first-page":"7615","DOI":"10.1038\/s41598-024-57551-8","article-title":"Gene targeting in adult organs using in vivo cleavable donor plasmids for CRISPR-Cas9 and CRISPR-Cas12a","volume":"14","author":"Ishibashi","year":"2024","journal-title":"Sci. Rep."},{"issue":"42","key":"10.1016\/j.leukres.2025.107646_bib60","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.18632\/oncotarget.6392","article-title":"ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts","volume":"6","author":"Valletta","year":"2015","journal-title":"Oncotarget"},{"issue":"7601","key":"10.1016\/j.leukres.2025.107646_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature17664","article-title":"Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9","volume":"533","author":"Paquet","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107646_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12703\/r\/9-20","article-title":"CRISPR-based strategies for targeted transgene knock-in and gene correction","volume":"9","author":"Lau","year":"2020","journal-title":"Fac. Rev."},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102138","article-title":"Recent advances in CRISPR-Cas9-based genome insertion technologies","volume":"35","author":"Chen","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7603","key":"10.1016\/j.leukres.2025.107646_bib64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"7681","key":"10.1016\/j.leukres.2025.107646_bib65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.leukres.2025.107646_bib66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nbt.4172","article-title":"Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction","volume":"36","author":"Koblan","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.leukres.2025.107646_bib67","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.omtn.2019.06.024","article-title":"Improving Editing Efficiency for the Sequences with NGH PAM Using xCas9-Derived Base Editors","volume":"17","author":"Liu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7785","key":"10.1016\/j.leukres.2025.107646_bib68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"7764","key":"10.1016\/j.leukres.2025.107646_bib69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41586-019-1323-z","article-title":"Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration","volume":"571","author":"Klompe","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib71","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2025.107646_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.leukres.2025.107646_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122387","article-title":"Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1\/PD-L1 antibodies","volume":"338","author":"Najafi","year":"2024","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29020454","article-title":"Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy","volume":"29","author":"Geng","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.leukres.2025.107646_bib76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtm.2022.05.005","article-title":"PAM-flexible dual base editor-mediated random mutagenesis and self-activation strategies to improve CRISPRa potency","volume":"26","author":"Lau","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"19","key":"10.1016\/j.leukres.2025.107646_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt721","article-title":"Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre\/LoxP cassette exchange in human-induced pluripotent stem cells","volume":"41","author":"Zhu","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.leukres.2025.107646_bib78","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"7587","key":"10.1016\/j.leukres.2025.107646_bib79","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2025.107646_bib80","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/nar\/gkab1291","article-title":"High-fidelity KKH variant of Staphylococcus aureus Cas9 nucleases with improved base mismatch discrimination","volume":"50","author":"Yuen","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.leukres.2025.107646_bib81","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.leukres.2025.107646_bib82","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41589-023-01279-5","article-title":"Sniper2L is a high-fidelity Cas9 variant with high activity","volume":"19","author":"Kim","year":"2023","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41587-023-01769-w","article-title":"Precise integration of large DNA sequences in plant genomes using PrimeRoot editors","volume":"42","author":"Sun","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.leukres.2025.107646_bib84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41592-023-02162-w","article-title":"Exonuclease-enhanced prime editors","volume":"21","author":"Truong","year":"2024","journal-title":"Nat. Methods"},{"key":"10.1016\/j.leukres.2025.107646_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-07259-6","article-title":"Improving prime editing with an endogenous small RNA-binding protein","author":"Yan","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.leukres.2025.107646_bib86","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41587-022-01574-x","article-title":"Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases","volume":"41","author":"Tou","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107646_bib87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107646_bib89","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"668","key":"10.1016\/j.leukres.2025.107646_bib91","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med"},{"issue":"5","key":"10.1016\/j.leukres.2025.107646_bib92","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long Terminal Repeat CRISPR-CAR-Coupled \"Universal\" T Cells Mediate Potent Anti-leukemic Effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.leukres.2025.107646_bib93","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"issue":"7926","key":"10.1016\/j.leukres.2025.107646_bib94","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.leukres.2025.107646_bib95","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/bloodadvances.2021006232","article-title":"CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma","volume":"6","author":"Guo","year":"2022","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2025.107646_bib96","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered Universal CD19\/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib97","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2025.107646_bib98","doi-asserted-by":"crossref","first-page":"1270843","DOI":"10.3389\/fimmu.2023.1270843","article-title":"Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia","volume":"14","author":"Calvino","year":"2023","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107646_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020334","article-title":"CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture","volume":"16","author":"Harfmann","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.leukres.2025.107646_bib100","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-23-0677","article-title":"Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion","volume":"12","author":"De Munter","year":"2024","journal-title":"Cancer Immunol. Res"},{"issue":"4","key":"10.1016\/j.leukres.2025.107646_bib101","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","article-title":"High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models","volume":"12","author":"Degagne","year":"2024","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.leukres.2025.107646_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216660","article-title":"Delivery of CD47-SIRPalpha checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma","volume":"585","author":"Lu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2025.107646_bib103","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.omtn.2022.06.003","article-title":"Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T(SCM)-enriched allogeneic CAR-T cells","volume":"29","author":"Madison","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.leukres.2025.107646_bib104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12951-024-02512-6","article-title":"BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma","volume":"22","author":"Lu","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"6481","key":"10.1016\/j.leukres.2025.107646_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.leukres.2025.107646_bib106","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jcyt.2022.07.008","article-title":"Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells","volume":"24","author":"Gurney","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.leukres.2025.107646_bib107","doi-asserted-by":"crossref","first-page":"1346810","DOI":"10.3389\/fbioe.2024.1346810","article-title":"Use of CRISPRoff and synthetic Notch to modulate and relay endogenous gene expression programs in engineered cells","volume":"12","author":"Shi","year":"2024","journal-title":"Front Bioeng. Biotechnol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:01:41Z","timestamp":1778623301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":107,"alternative-id":["S0145212625000062"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107646","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood cancer therapy with synthetic receptors and CRISPR technology","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107646"}}